|
EP0283801A3
(en)
*
|
1987-03-27 |
1990-05-30 |
Abbott Laboratories |
Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
|
|
US5236899A
(en)
*
|
1987-11-16 |
1993-08-17 |
Merck & Co., Inc. |
6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
|
|
KR0148748B1
(ko)
*
|
1988-09-16 |
1998-08-17 |
장 크라메르, 한스 루돌프 하우스 |
사이클로스포린을 함유하는 약학조성물
|
|
US6007840A
(en)
*
|
1988-09-16 |
1999-12-28 |
Novartis Ag |
Pharmaceutical compositions comprising cyclosporins
|
|
BE1003009A5
(fr)
*
|
1989-02-09 |
1991-10-22 |
Sandoz Sa |
Nouvelles compositions pharmaceutiques a base de cyclosporines.
|
|
US5540931A
(en)
*
|
1989-03-03 |
1996-07-30 |
Charles W. Hewitt |
Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
|
|
GB8916901D0
(en)
*
|
1989-07-24 |
1989-09-06 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
|
US5122511A
(en)
*
|
1990-02-27 |
1992-06-16 |
Merck & Co., Inc. |
Immunosuppressive cyclosporin analogs with modified amino acids at position-8
|
|
US6262022B1
(en)
|
1992-06-25 |
2001-07-17 |
Novartis Ag |
Pharmaceutical compositions containing cyclosporin as the active agent
|
|
GB9204466D0
(en)
*
|
1992-03-02 |
1992-04-15 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
|
GB9208712D0
(en)
*
|
1992-04-22 |
1992-06-10 |
Sandoz Ltd |
Pharmaceutical compositions containing cyclosporin derivates
|
|
DK0642332T3
(da)
*
|
1992-05-13 |
1997-06-16 |
Sandoz Ltd |
Ophthalmiske præparater indeholdende cyclosporin
|
|
CZ278863B6
(en)
*
|
1992-09-07 |
1994-07-13 |
Galena |
Medicinal preparations with n-methylated cyclic undecapeptides
|
|
ES2168271T3
(es)
|
1992-09-25 |
2002-06-16 |
Novartis Ag |
Composiciones farmaceuticas que contienen ciclosporinas.
|
|
US20020099067A1
(en)
*
|
1993-07-08 |
2002-07-25 |
Ulrich Posanski |
Pharmaceutical compositions for sparingly soluble therapeutic agents
|
|
GB9318612D0
(en)
*
|
1993-09-08 |
1993-10-27 |
Sandoz Ltd |
An assay
|
|
US6187547B1
(en)
|
1993-09-08 |
2001-02-13 |
Novartis Ag |
Assay kit
|
|
DE69535592T2
(de)
*
|
1994-03-25 |
2008-06-12 |
Isotechnika, Inc., Edmonton |
Verbesserung der effektivität von arzneimitteln duren deuterierung
|
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
ATE218359T1
(de)
|
1994-11-03 |
2002-06-15 |
Novartis Erfind Verwalt Gmbh |
Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
|
|
GR1002687B
(el)
*
|
1995-04-17 |
1997-05-06 |
Novartis Ag (Novartis Sa) (Novartis Inc.) |
Διαδικασια παραγωγης.
|
|
US6245805B1
(en)
|
1995-10-26 |
2001-06-12 |
Baker Norton Pharmaceuticals, Inc. |
Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
|
|
US6395770B1
(en)
|
1995-10-26 |
2002-05-28 |
Baker Norton Pharmaceuticals, Inc. |
Method and compositions for administering taxanes orally to human patients
|
|
DE19549852B4
(de)
|
1995-11-29 |
2009-06-04 |
Novartis Ag |
Cyclosporin enthaltende Präparate
|
|
GB9601120D0
(en)
*
|
1996-01-19 |
1996-03-20 |
Sandoz Ltd |
Organic compounds
|
|
TR199901686T2
(xx)
*
|
1997-01-30 |
1999-09-21 |
Norvartis Ag |
Esasen ya�s�z farmakolojik kompozisyonlar� i�eren sert jelatin kaps�ller.
|
|
DE69840586D1
(de)
*
|
1997-10-08 |
2009-04-02 |
Isotechnika Inc |
Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
|
|
US20030220234A1
(en)
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
|
CA2306448A1
(en)
|
1997-10-16 |
1999-04-22 |
Board Of Regents, The University Of Texas System |
Models and treatments for cardiac hypertrophy in relation with nf-at3 function
|
|
PT1091975E
(pt)
|
1998-07-01 |
2006-05-31 |
Debiopharm Sa |
Nova ciclosporina com um perfil de actividade melhorado
|
|
US7026290B1
(en)
|
1998-12-30 |
2006-04-11 |
Dexcel Ltd. |
Dispersible concentrate for the delivery of cyclosprin
|
|
US6255280B1
(en)
*
|
1999-04-08 |
2001-07-03 |
University Of Kentucky Research Foundation |
Protection against traumatic brain injury
|
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
|
US6784156B2
(en)
|
2001-03-05 |
2004-08-31 |
Enanta Pharmaceuticals, Inc. |
Cyclosporins for the treatment of respiratory diseases
|
|
GB0113663D0
(en)
*
|
2001-06-05 |
2001-07-25 |
Novartis Ag |
Use of organic compounds
|
|
US6809077B2
(en)
*
|
2001-10-12 |
2004-10-26 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogs for the treatment of autoimmune diseases
|
|
US20030087813A1
(en)
|
2001-10-12 |
2003-05-08 |
Or Yat Sun |
Cyclosporin analogs for the treatment of lung diseases
|
|
SI1436321T1
(sl)
*
|
2001-10-19 |
2006-12-31 |
Isotechnika Inc |
Sinteza analogov ciklosporina
|
|
AU2002333098B2
(en)
*
|
2001-10-19 |
2006-03-16 |
Isotechnika Pharma Inc. |
Novel cyclosporin analog microemulsion preconcentrates
|
|
PT1436322E
(pt)
*
|
2001-10-19 |
2008-10-23 |
Isotechnika Inc |
Misturas de análogos da ciclosporina e sua utilização como agentes imunomodulantes
|
|
AU2007221839B2
(en)
*
|
2001-10-19 |
2011-05-12 |
Aurinia Pharmaceuticals Inc. |
Synthesis of cyclosporin analogs
|
|
US7012065B2
(en)
|
2003-02-07 |
2006-03-14 |
Enanta Pharmaceuticals, Inc. |
Cyclosporins for the treatment of immune disorders
|
|
US7538084B2
(en)
*
|
2003-03-17 |
2009-05-26 |
Amr Technology, Inc. |
Cyclosporins
|
|
TW200505946A
(en)
*
|
2003-04-08 |
2005-02-16 |
Hoffmann La Roche |
Process for preparation of cyclosporin a analog
|
|
EA017893B1
(ru)
*
|
2004-04-08 |
2013-04-30 |
Лаборатуар Сероно Са |
Композиции, содержащие ингибитор jnk и циклоспорин
|
|
US20060014677A1
(en)
*
|
2004-07-19 |
2006-01-19 |
Isotechnika International Inc. |
Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
|
|
US7378391B2
(en)
*
|
2004-09-29 |
2008-05-27 |
Amr Technology, Inc. |
Cyclosporin alkyne analogues and their pharmaceutical uses
|
|
US7511013B2
(en)
*
|
2004-09-29 |
2009-03-31 |
Amr Technology, Inc. |
Cyclosporin analogues and their pharmaceutical uses
|
|
EP1812037A4
(en)
*
|
2004-10-06 |
2009-11-11 |
Amr Technology Inc |
ALKYNES OF CYCLOSPORINE AND THEIR USEFUL AS PHARMACEUTICAL AGENTS
|
|
MX2007007262A
(es)
*
|
2004-12-17 |
2007-10-19 |
Isotechnika Inc |
Metabolitos de analogos de ciclosporina.
|
|
US7696165B2
(en)
*
|
2006-03-28 |
2010-04-13 |
Albany Molecular Research, Inc. |
Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
|
|
US7696166B2
(en)
*
|
2006-03-28 |
2010-04-13 |
Albany Molecular Research, Inc. |
Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
|
|
US20080206287A1
(en)
*
|
2006-09-18 |
2008-08-28 |
Reed John C |
Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
|
|
AU2008204344B2
(en)
*
|
2007-01-04 |
2013-01-31 |
Debiopharm Sa |
Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
|
|
TW200932240A
(en)
|
2007-10-25 |
2009-08-01 |
Astellas Pharma Inc |
Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
|
|
BRPI0911709A2
(pt)
*
|
2008-07-30 |
2017-06-20 |
Isotechnika Labs Inc |
composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
|
|
KR20110071014A
(ko)
|
2008-10-17 |
2011-06-27 |
위스콘신 얼럼나이 리서어치 화운데이션 |
생물학적으로 활성인 알파-베타 펩티드의 제조 방법
|
|
JP5780969B2
(ja)
*
|
2008-12-31 |
2015-09-16 |
サイネクシス，インコーポレーテッド |
シクロスポリンａの誘導体
|
|
EP2391376A4
(en)
*
|
2009-01-30 |
2012-08-01 |
Enanta Pharm Inc |
ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION
|
|
US8481483B2
(en)
*
|
2009-02-19 |
2013-07-09 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues
|
|
US8685917B2
(en)
*
|
2009-07-09 |
2014-04-01 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues
|
|
US8367053B2
(en)
*
|
2009-07-09 |
2013-02-05 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues
|
|
US8349312B2
(en)
*
|
2009-07-09 |
2013-01-08 |
Enanta Pharmaceuticals, Inc. |
Proline substituted cyclosporin analogues
|
|
DE102009037551A1
(de)
*
|
2009-08-17 |
2011-02-24 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Cyclosporinderivate
|
|
US8623814B2
(en)
*
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
|
WO2011141891A1
(en)
|
2010-05-12 |
2011-11-17 |
Debio Recherche Pharmaceutique S.A. |
Use of cycloundecadepsipeptide compounds
|
|
CN107496902B
(zh)
|
2010-12-15 |
2022-01-18 |
康卓维尔制药公司 |
在氨基酸1和3位修改的环孢菌素类似分子
|
|
WO2012145427A1
(en)
|
2011-04-18 |
2012-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods to treat cancer using cyclosporine and cyclosporine derivatives
|
|
JP2015532277A
(ja)
|
2012-09-29 |
2015-11-09 |
ノバルティス アーゲー |
環状ペプチドおよび医薬としてのその使用
|
|
WO2014085623A1
(en)
|
2012-11-28 |
2014-06-05 |
Enanta Pharmaceuticals, Inc. |
Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
|
|
KR20160045136A
(ko)
|
2013-08-26 |
2016-04-26 |
이난타 파마슈티칼스, 인코포레이티드 |
C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CN107001478B
(zh)
|
2014-10-14 |
2022-01-11 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
US9669095B2
(en)
|
2014-11-03 |
2017-06-06 |
Enanta Pharmaceuticals, Inc. |
Cyclosporin analogues for preventing or treating hepatitis C infection
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017027973A1
(en)
|
2015-08-18 |
2017-02-23 |
Novation Pharmaceuticals Inc. |
Benzopyran derivatives and uses thereof
|
|
LT3370768T
(lt)
|
2015-11-03 |
2022-05-25 |
Janssen Biotech, Inc. |
Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
|
|
US20180371093A1
(en)
|
2015-12-17 |
2018-12-27 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
CN114208781B
(zh)
*
|
2022-01-20 |
2022-12-20 |
河南农业大学 |
一种抑制草地贪夜蛾龄期的方法及其应用
|